Last reviewed · How we verify
Timolol 0.5% Ophthalmic Solution
Timolol is a non-selective beta-adrenergic receptor antagonist that reduces intraocular pressure by decreasing aqueous humor production in the eye.
Timolol is a non-selective beta-adrenergic receptor antagonist that reduces intraocular pressure by decreasing aqueous humor production in the eye. Used for Open-angle glaucoma, Ocular hypertension.
At a glance
| Generic name | Timolol 0.5% Ophthalmic Solution |
|---|---|
| Also known as | timoptic, Timoptol, TIMOLOL |
| Sponsor | University of California, Davis |
| Drug class | Beta-adrenergic antagonist |
| Target | Beta-1 and beta-2 adrenergic receptors |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Timolol blocks beta-1 and beta-2 adrenergic receptors on the ciliary body epithelium, which reduces the rate of aqueous humor secretion. This leads to a decrease in intraocular pressure, making it effective for treating glaucoma and ocular hypertension. The ophthalmic solution formulation allows direct topical application to the eye for local therapeutic effect.
Approved indications
- Open-angle glaucoma
- Ocular hypertension
Common side effects
- Ocular irritation or discomfort
- Blurred vision
- Conjunctival hyperemia
- Systemic beta-blockade effects (bradycardia, bronchospasm in susceptible patients)
Key clinical trials
- Phase 3 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant (PHASE3)
- Efficacy of 0.5% Topical Timolol Eye Drops in the Treatment of Post-Inflammatory Erythema Following Acne Vulgaris (EARLY_PHASE1)
- Assessing the Impact of Dosage Frequency of Propranolol on Sleep Patterns in Patients With Infantile Hemangiomas (PHASE4)
- Aqueous Humor Dynamic Components That Determine Intraocular Pressure Variance (PHASE4)
- Phase 2/Phase 3 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant (PHASE2, PHASE3)
- Study of an Investigational Product, QLS-111, Provided as an Eyedrop, for Treatment of Normal Tension Glaucoma (NTG) (PHASE2)
- Efficacy and Safety of Topical Timolol in Secondary Intention Surgical Wounds Healing (PHASE2)
- Phase 2 Study of BL1107 Eye Drops vs. Timolol in Adults With Primary Open Angle Glaucoma or Ocular Hypertension (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Timolol 0.5% Ophthalmic Solution CI brief — competitive landscape report
- Timolol 0.5% Ophthalmic Solution updates RSS · CI watch RSS
- University of California, Davis portfolio CI